NASDAQ:ZURA

Zura Bio Q4 2025 Earnings Results & Report

Zura Bio logo
$1.08 -0.16 (-12.90%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 +0.00 (+0.09%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zura Bio missed analyst earnings expectations in its Q4 2025 results, released March 16, 2026. The company reported EPS of -$0.49 versus the -$0.18 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Zura Bio EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.31
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Zura Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Zura Bio Q4 2025 Earnings FAQ

Zura Bio (NASDAQ:ZURA) reported earnings of -$0.49 per share for Q4 2025, missing the consensus estimate of -$0.18. The report was announced on Monday, March 16, 2026.

Zura Bio Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Zura Bio (ZURA) Set to Release Earnings on Thursday
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. Its research targets immune pathways that may contribute to a range of chronic conditions.

The company’s investigational pipeline includes tibulizumab (ZB-106), a dual-targeting antibody designed to inhibit BAFF and IL-17A, and ZB-168, an antibody targeting the IL-7 receptor alpha. These candidates are being developed for potential use in autoimmune and inflammatory conditions.

Zura Bio became a publicly traded company in 2023 through a business combination with JATT Acquisition Corp. Its drug candidates remain investigational and have not been approved for commercial use.

View Zura Bio Profile